TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32851257
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone
Study: 34260808
Drug: Nutraceutical containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical containing a blend of Glycine max, Cimicifuga racemosa, Vitex agnus-castus, and Oenothera biennis extracts administered over a 12-week period
Study: 32770246
Drug: Combination Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination Nicotine Replacement Therapy (NRT)
Study: 35312968
Drug: Sublingual atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual atropine sulfate 1% ophthalmic solution (0.5 mg and 1.0 mg)
Study: 35312968
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg intravenous (IV) atropine dose
Study: 35312968
Drug: Sublingual atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual atropine sulfate 1% ophthalmic solution
Study: 34140765
Drug: Pyrotinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (80 mg single dose on days 1 and 9) co-administered with Itraconazole (200 mg once-daily from days 6 to 22)
Study: 34140765
Drug: Pyrotinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib (80 mg single dose on days 1 and 9)
Study: 32810739
Drug: MitoQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (20 mg, 1 hour pre-exercise, chronic supplementation for 21 days)
Study: 33859520
Drug: Oral resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol (480 mg per day for 4 days)
Study: 34181475
Drug: XAV-19 at
Normalized name: crospovidone (19 MPA.S at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAV-19 at 0.5 mg/kg at day 1 and day 5 (group 1)
Study: 34181475
Drug: XAV-19 at
Normalized name: crospovidone (19 MPA.S at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAV-19 at 2 mg/kg at day 1 and day 5 (group 2)
Study: 34181475
Drug: XAV-19 at
Normalized name: crospovidone (19 MPA.S at 5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAV-19 at 2 mg/kg at day 1 (group 3)
Study: 33153527
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy–Emotion Development (PCIT-ED)
Study: 33217031
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (group L)
Study: 35512155
Drug: Standard dosing:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing: 1 g of IV TXA 30 min before skin incision, and 1 g at postoperative 30 min and 3 h.
Study: 35512155
Drug: Weight-based dosing:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing: 10 mg/kg IV TXA 30 min before skin incision, and 10 mg/kg at postoperative 30 min and 3 h.
Study: 35512155
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (standard and weight-based dosing of IV TXA).
Study: 35758436
Drug: Neurological Speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated about a month after stroke
Study: 35758436
Drug: Neurological Speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological Speech and Language Therapy (SLA) for 4 weeks, initiated more than 6 months after stroke (late therapy)
Study: 34037294
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for a given vaccine
Study: 32089848
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention in social insurance medicine
Study: 32139090
Drug: BSC-pre (halamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSC-pre (halamine antimicrobial curtains sprayed twice weekly with sodium hypochlorite)
Study: 33468148
Drug: Foot massage
Normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot massage treatment (10-min daily for four weeks using sweet almond oil)
Study: 33468148
Drug: Foot massage
Normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot massage treatment
Study: 33468148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no foot massage treatment)
Study: 35666314
Drug: OPERA® dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPERA® dietary supplement (α‐Lipoic acid, Boswellia serrata, Methylsulfonylmethane, and Bromelain) taken once a day for six months (T0 to T3)
Study: 35666314
Drug: OPERA® dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPERA® dietary supplement
Study: 32926462
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg)
Study: 37323710
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard in-hospital treatment)
Study: 33445146
Drug: CT (Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Concurrent Training)
Study: 33445146
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + EL (Concurrent Training + Eurycoma longifolia)
Study: 32063157
Drug: Nebulised normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised normal saline administered hourly
Study: 34323341
Drug: Modified WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified WHO cholera solution
Study: 34955173
Drug: Vaginal Stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Stretching with Photobiomodulation Therapy (PBMT)
Study: 32620210
Drug: GC-avelumab (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC-avelumab (gemcitabine 1000 mg/m2 on days 1 and 8, Cisplatin 70 mg/m2 on day 1, plus Avelumab 10 mg/kg every 3 weeks)
Study: 32620210
Drug: GC (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC (gemcitabine 1000 mg/m2 on days 1 and 8, Cisplatin 70 mg/m2 on day 1)
Study: 36137654
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (preferred by interventional neuroradiologists)
Study: 35152197
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with induction chemotherapy (Cisplatin 75 mg/m2 and Paclitaxel 175 mg/m2 every 21 days) followed by concurrent chemoradiotherapy (66Gy in 33 fractions for 6.5 weeks)
Study: 35152197
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (Cisplatin 40 mg/m2 intravenous during chest radiotherapy of 66Gy in 33 fractions for 6.5 weeks)
Study: 35063882
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy alone
Study: 32881641
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy, with anti-SARS-CoV-2 titers of >1:640 to >1:1000, dosage and duration not specified.
Study: 32881641
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy, details on dosage and duration not specified.
Study: 32915939
Drug: Tretinoin lotion
Normalized name: tretinoin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin lotion 0.05%
Study: 35638317
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg daily for 18 weeks)
Study: 38770686
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or standard treatment not specified)
Study: 35093946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of Rosuvastatin in addition to SSRIs therapy
Study: 35093946
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to SSRIs therapy
Study: 35093946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of Rosuvastatin
Study: 34367303
Drug: Compound Lidocaine
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Lidocaine Cream (CLC)
Study: 36079732
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing Sambucus nigra, zinc, tyndallized Lactobacillus acidophilus (HA122), arabinogalactans, vitamin D, vitamin E, and vitamin C for 30 days
Study: 33713211
Drug: New-Generation Drug-Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: New-Generation Drug-Eluting Stents (DES)
Study: 39593225
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily routine (control group)
Study: 34147344
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicines (IH)
Study: 32925621
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (mifepristone and misoprostol)
Study: 32925621
Drug: Monotherapy (misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (misoprostol alone)
Study: 32073619
Drug: ASP‐p iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP‐p iron absorption
Study: 33613521
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) as adjunct therapy during the first two months of anti-TB treatment
Study: 35329107
Drug: Synbiotic (Gasteel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (Gasteel Plus®) administered for 30 days
Study: 35329107
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 30 days
Study: 33038950
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous bolus of 10% dextrose at 5 mL/kg followed by a 24-h maintenance infusion of 10% dextrose at 100 mL/kg for the first 10 kg of bodyweight, 50 mL/kg for the next 10 kg, and 20 mL/kg for each subsequent kg of bodyweight.
Study: 36155131
Drug: Reduced-dose glucocorticoid
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose glucocorticoid regimen
Study: 36155131
Drug: Standard-dose glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose glucocorticoid regimen
Study: 34010183
Drug: ACEI/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB treatment
Study: 38319842
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg/day
Study: 32062173
Drug: High-dose TxA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TxA (30 mg/kg bolus, 16 mg/kg/h maintenance, 2 mg/kg pump prime)
Study: 32062173
Drug: Low-dose TxA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TxA (10 mg/kg bolus, 2 mg/kg/h maintenance, 1 mg/kg pump prime)
Study: 32062173
Drug: High-dose TxA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TxA
Study: 32062173
Drug: Low-dose TxA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TxA
Study: 33332190
Drug: Subsequent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapy (both groups)
Study: 33332190
Drug: Subsequent targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent targeted therapy
Study: 33479925
Drug: Counseling on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling on hypoglycemia treatment or avoidance of driving
Study: 36137638
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) and prednisolone
Study: 36137638
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin (5%) and placebo tablets
Study: 32005604
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received a head turban, sleeping socks, a heated blanket, a Bair Hugger for forced-air warming, and a Mega Acer kit for warming intravenous fluid.
Study: 32564571
Drug: Ticagrelor 45
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 45 mg bid
Study: 33150481
Drug: miR-367 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: miR-367 treatment in erythrocyte lysate-treated microglia
Study: 33100326
Drug: HDL increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL increase (1 SD = 12.26 mg/dL)
Study: 33100326
Drug: TG increase
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG increase (1 SD = 112.33 mg/dL)
Study: 33875433
Drug: NTM-1632 (0.033
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1632 (0.033 mg/kg)
Study: 33875433
Drug: NTM-1632 (0.165
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1632 (0.165 mg/kg)
Study: 33875433
Drug: NTM-1632 (0.330
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-1632 (0.330 mg/kg)
Study: 33568226
Drug: Encapsulated iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated iodine complex of 200 mg (arm A)
Study: 33568226
Drug: Iodine complex
Normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine complex syrup form 40 ml (arm B)
Study: 33568226
Drug: Iodine complex
Normalized name: Undecoylium chloride iodine complex
DrugBank: Undecoylium chloride iodine complex (DB09377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine complex throat spray of 2 puffs (arm C)
Study: 33568226
Drug: Empty capsule
Normalized name: Empty Capsule Size 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty capsule (arm D) as placebo
Study: 35445723
Drug: Pixantrone 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone 180 mg/m2 every 3 weeks (group A)
Study: 35445723
Drug: Pixantrone 85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B)
Study: 34499820
Drug: Albuterol nebulized
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulized with 3% hypertonic saline (HSS)
Study: 34499820
Drug: Albuterol nebulized
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulized with normal saline solution (NSS)
Study: 36104128
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of LC-Plasma-containing capsule, 200 mg/day, for 14 days
Study: 36104128
Drug: Placebo capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, for 14 days
Study: 34229051
Drug: NIMO‐CCRT (CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIMO‐CCRT (CCRT with 200 mg of nimotuzumab administered weekly by intravenous infusion)
Study: 34229051
Drug: CCRT (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT (65 Gy thoracic radiation over 5 weeks concurrent with docetaxel and cisplatin)
Study: 33253664
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection 2 mg every 4 weeks (2q4)
Study: 33253664
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection 2 mg every 8 weeks (2q8)
Study: 33759389
Drug: Phenotype-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenotype-guided treatment with antiobesity medications (phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, liraglutide)
Study: 33759389
Drug: Non-phenotype-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-phenotype-guided treatment with antiobesity medications
Study: 35963206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatments)
Study: 32031726
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of MMR vaccine
Study: 37804858
Drug: Faster-acting insulin
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster-acting insulin aspart (faster aspart)
Study: 32332810
Drug: Motor Imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor Imagery (MI) training for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Study: 32332810
Drug: Health Education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Education (HE) for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Study: 36041708
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg on days 1-7, 0.5 mg on days 8-14
Study: 36041708
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg per day for 14 days
Study: 36041708
Drug: Colchicine 2
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 2 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Study: 36041708
Drug: Colchicine 3
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 3 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Study: 33704936
Drug: One-step screening
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step screening (75-g glucose load, fasting state)
Study: 33704936
Drug: Two-step screening
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step screening (50-g glucose load, nonfasting state followed by 100-g glucose load, fasting state)
Study: 32856709
Drug: Low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salt diet (1,500 mg/d)
Study: 32856709
Drug: Medium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium salt diet (2,400 mg/d)
Study: 32856709
Drug: High salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salt diet (3,300 mg/d)
Study: 35378544
Drug: Intensive mirror
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive mirror therapy (5 times/week for 6 weeks)
Study: 35378544
Drug: Spaced mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spaced mirror therapy (3 times/week for 10 weeks)
Study: 33128635
Drug: DS‐25OHD <
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS‐25OHD < 40 nmol/L
Study: 35230249
Drug: Community volunteers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community volunteers (CVs) tracking children's vaccination status and demographic movements, organizing monthly catch-up immunization sessions via WhatsApp.
Study: 33818221
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy (HT)
Study: 35509819
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng formulation
Study: 35509819
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng formulation with 1,2‐hexanediol
Study: 35509819
Drug: Hydrogel formulation
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel formulation
Study: 32890813
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (more than six cycles)
Study: 34695622
Drug: Pharmaceutical method
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical method (prostaglandins)
Study: 33367539
Drug: Orthodontic space
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orthodontic space closure treatment (TG)
Study: 32613752
Drug: Cinpanemab (BIIB054)
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab (BIIB054) 250 mg every 4 weeks
Study: 32613752
Drug: Cinpanemab (BIIB054)
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab (BIIB054) 1,250 mg every 4 weeks
Study: 32613752
Drug: Cinpanemab (BIIB054)
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab (BIIB054) 3,500 mg every 4 weeks
Study: 32613752
Drug: Cinpanemab (BIIB054)
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab (BIIB054) up to 90 mg/kg
Study: 32812388
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.25 mg/kg)
Study: 32619413
Drug: Immunomodulator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulator therapy (in addition to allocated treatment)
Study: 35902900
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment 1
Study: 35902900
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment 2
Study: 35902900
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment 3
Study: 35902900
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment 1, 2, and 3